Delta4 Identifies a Potential New Therapeutic Option for Focal Segmental Glomerulosclerosis (FSGS) using computational Hyper-C Drug Discovery Platform
Delta4, a digital drug discovery company, identified a potential therapeutic option for Focal Segmental Glomerulosclerosis (FSGS) using their Hyper-C AI software platform. The anti-platelet drug clopidogrel was among the top predictions and was shown to alleviate disease progression in an accepted FSGS animal model, suggesting it is a promising candidate for clinical trials. May 24, […]
Delta4 CEO Kurt Herpel Featured in Insightscare Magazine: A Vision for the Future of Drug Discovery
We are incredibly proud to share that our esteemed CEO, Kurt Herpel, has recently been profiled in Insightscare Magazine. In the article titled “Kurt Herpel: Revolutionizing Drug Discovery Through Artificial Intelligence,” Kurt shares his vision for the future of drug discovery, highlighting the transformative potential of artificial intelligence (AI) in advancing healthcare solutions. AI and […]
Delta4 expands Team and tackles new indications
A Welcome to Our Newest Member Following our Financing in March 2021 and our move into new premises in July 2021, we are continuing to expand our footprint and our capabilities. To that effect, I am happy to announce that Samuel Walter has joined the team as Data Scientist. Samuel will finish his Ph.D. in […]
Office News – July ’21
We are excited to announce that Delta4 has moved into a new office in the 8th district, close to the city centre. The new headquarters is also within walking distance of the Medical University Vienna / General Hospital Vienna (AKH), which allows us to smoothly continue our close cooperation with this important institution. Furthermore, it gives […]
Alfred Steininger to Join Delta4 as CFO
We are very pleased to introduce Alfred Steininger as our new Chief Financial Officer, starting in mid-July 2021. Alfred brings to Delta4 a deep financial expertise from his 20 years with banks in Austria and Switzerland, and as a CFO and Business Angel Investor working with start-ups and young businesses. We are looking forward to […]
FSGS and COVID-19 programs ready for Phase II studies
We are proud to announce further progress in our current drug discovery and development programs. In late 2020, Delta4 filed four patent applications for compounds and combinations of compounds for the treatment of FSGS, a rare kidney disease with only limited therapeutic options, and COVID-19. Today, drug candidates from both programs have been biologically validated […]
COVID-19 – Call to Action
The global crisis caused by the SARS-Cov2 outbreak requires rapidly applicable therapeutics. Available approved drug substances represent one of the more realistic paths to clinical use within weeks or months. Delta4 is aiming to use its digital drug development platform to screen repurposing opportunities for COVID-19. Currently our computational biology staff is preparing to curate […]